Acceleron Pharma Inc's ACE-083 drug trials "did not achieve statistically significant improvements in functional endpoints relative to placebo" with CMT patients, so it will no longer be developed.
ACE-083 Trials Show no Benefit
Tag: ACE-083
ACE-083 was a drug developed by Acceleron Pharma Inc. to increase muscle mass in people with muscle atrophy from MD and CMT. In 2019-20, clinical trials showed insufficient benefits to continue development of the drug.
Second Phase 3 Clinical Trial for CMT1A “Pleodrug”
After the setback of having to do a second Phase 3 clinical trial, Pharnext's ongoing drug trials for PXT3003 show positive results in people with CMT1A.
